A study of patients who initiated dialysis in the Southeast United States found that those receiving care at for-profit facilities were 16% less likely to receive a kidney transplant referral than patients at non-profit facilities.
Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.
Symptoms including bother, difficulty concentrating, thinking everything is an effort, and feeling lonely significantly associated with rapid kidney function decline.
In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
The prevalence of CKD-related sarcopenia may be higher than ageing-related sarcopenia.
In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.
In a study of middle-aged adults, serum uric acid levels less than 4.0 and 10.0 mg/dL or higher in men and less than 4.0 and 8.0 mg/dL or higher in women were significantly associated with increased risks for chronic kidney disease.
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
Male sex is independently associated with a nearly 2-fold increased risk for in-hospital death, among patients with CKD.